SHANGHAI, China, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that two studies will be presented at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO), which will be held September 19-23, 2018, at the Xiamen International Conference and Exhibition Center (XICEC) in Xiamen, China. Zai Lab will also present one study at the IASLC 19th World Conference on Lung Cancer (WCLC), which will be held September 23-26, 2018, at the Metro Toronto Convention Centre in Toronto, Canada.
|Title: A Phase 1 study to evaluate the pharmacokinetics (PK) and safety of niraparib (ZL-2306) in Chinese patients with epithelial ovarian cancer (OC)|
|Presentation Date and Time: Sept. 21st at 3:36pm|
|Abstract Number: 936|
|Title: Exploring the efficacy and safety of different doses of ZL-2301 (Brivanib) in advanced hepatocellular carcinoma (HCC) patients with systemic treatment failure or intolerance|
|Presentation Date and Time: Sept. 22nd at 4:30pm|
|Abstract number: 1268|
|Title: A Phase 3 study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients|
|Presentation Date and Time: Sept. 23rd morning session (7am to 11:15am)|
|Abstract number: 12119|
About ZL-2306 (niraparib)
ZL-2306 (niraparib) is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) PARP 1/2 inhibitor. Niraparib was approved in March 2017 by the FDA in the U.S. and by the EMA in the EU under the trade name ZEJULA® in November 2017 as a maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Based on the approval status in the U.S. and EU, Zai Lab submitted a market registration application for niraparib in Hong Kong and plans to launch and commercialize niraparib in Hong Kong in the second half of 2018. Zai Lab believes ZL-2306 (niraparib) has the potential to be a first-in-class Category 1 drug for treatment across multiple solid tumor types in China.
About ZL-2301 (Brivanib)
ZL-2301 (Brivanib) is an oral, small molecule dual target tyrosine kinase inhibitor, or TKI. Zai Lab licensed exclusive rights for China, Hong Kong, Macau and Taiwan from Bristol Myers Squibb.ZL-2301 (Brivanib) has been tested in 4 phase III studies in hepatocellular cancer and showed anti-tumor activity and manageable drug safety. Based on Zai Lab’s review of the results from Bristol-Myers Squibb’s development program for ZL-2301 (Brivanib), its understanding of the etiology and current standard of care of HCC in Chinese patients and its ongoing research, Zai Lab believes that ZL-2301(Brivanib) has the potential to be an effective treatment option for Chinese HCC patients and merits further clinical trials. In the second quarter of 2017 Zai Lab initiated a Phase II trial of ZL-2301(Brivanib) as a second-line treatment for advanced HCC patients in China.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.
Zai Lab Forward-Looking Statements
This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding business strategy, plans and objectives for future operations and other statements containing words such as "anticipates", “believes”, "expects", “plans” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab's expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab’s ability to obtain additional future funding, (2) Zai Lab’s results of clinical and pre-clinical development of its drug candidates, (3) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab’s drug candidates, (4) Zai Lab’s ability to generate revenue from its drug candidates, and (5) other factors discussed in Zai Lab's Annual Report on Form 20-F for the fiscal year ended December 31, 2017 and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab’s expectations and assumptions to change and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab’s views as of any date subsequent to the date of this press release.
For more information, please contact:
ZAI LAB CONTACTS:
+86 137 6151 2501
Media: Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006, ext. 364, email@example.com
Investors: Jill Steier
Burns McClellan, on behalf of Zai Lab
212-213-0006, ext. 367, firstname.lastname@example.org
Zai Lab Limited